UCG / Contributor / Getty Images Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 vaccine. Moderna's Spikevax KP.2 targets the KP.2 variant of ...

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...

We apologize, but this video has failed to load. The mRNA vaccine, called Spikevax, has been reformulated to target the KP.2 subvariant of Omicron, the agency said. It replaces the previous ...

The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...

As of 11:21 AM EDT. Market Open. Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects ...

On the heels of the nation’s biggest summer COVID surge—test positivity peaked at 17.8% the week ended Aug. 10—help has arrived. The 2024–25 coronavirus vaccines, initially anticipated ...

Spikevax includes an update to the antigen to combat the latest version of the Omicron variant of the virus. Other vaccines from Pfizer and Novavax are currently being reviewed. Police are asking ...

SPIKEVAX ® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians this fall and winter season. Moderna will promptly begin ...